---
title: "Tirzepatide (Mounjaro) and Liver Impairment: Dose Guidance"
description: "This review covers tirzepatide (Mounjaro) dosing across Child-Pugh classes A, B, and C, with pharmacokinetics and FDA labeling on dose adjustment."
url: https://healthrx.com/mounjaro/hepatic-impairment
publisher: HealthRX.com
---


HealthRX.com

No dose change is labeled for liver impairment

[Print or save as PDF](https://healthrx.com/printables/mounjaro/hepatic-impairment?print=1)

From the public record

Liver terms in FDA adverse event reports for Mounjaro

Of 97,440 adverse event reports FDA had received for Mounjaro through 2026-10-28, 1,177 (1.2%) name at least one liver term. The terms named most often are alanine aminotransferase increased (202), hepatic enzyme increased (195) and aspartate aminotransferase increased (119). Across every medicine in the database the same terms appear in 2.3% of reports.

Liver terms in FDA adverse event reports for Mounjaro: the figures

| Measure | Value | Note |
| --- | --- | --- |
| Reports naming at least one liver term | 1,177 |  |
| Share of all reports for Mounjaro | 1.2% | of 97,440 reports |
| Same terms across every medicine in FAERS | 2.3% | share of all reports in the database, for context |
| Alanine aminotransferase increased | 202 reports |  |
| Hepatic enzyme increased | 195 reports |  |
| Aspartate aminotransferase increased | 119 reports |  |
| Jaundice | 119 reports |  |
| Hepatitis | 92 reports |  |

Source: [FDA Adverse Event Reporting System (FAERS) via openFDA](https://open.fda.gov/data/faers/), data as of Oct 28, 2026

How this was calculated

Counted FAERS reports for this medicine that name any of 23 reaction terms about liver, then each term on its own. A report can name several terms. Reports are unverified and do not show cause.

Scope: Reports with the product name recorded as Mounjaro naming any of 23 MedDRA liver terms, all years to 2026-10-28

[See the public record for Tirzepatide](https://healthrx.com/data/tirzepatide)

HealthRX.com quick answer. Mounjaro does not need a dose adjustment for hepatic impairment, according to its label [1]. A single-dose study in people with Child-Pugh A, B or C impairment found tirzepatide exposure similar to that in people with normal liver function [2].

At a glance

- Starting dose / 2.5 mg subcutaneously once weekly [1]
- Titration / 2.5 mg increments after at least 4 weeks on the current dose [1]
- Maximum adult dose / 15 mg once weekly [1]
- Hepatic impairment / no dose adjustment per the Mounjaro label [1]
- Hepatic PK study / 32 participants; single 5 mg dose; Child-Pugh A, B and C [2]
- Metabolism / proteolytic cleavage of the peptide backbone, beta-oxidation of the fatty diacid and amide hydrolysis; not CYP [1]
- Contraindications / personal or family history of MTC or MEN 2; serious hypersensitivity [1]
- Labeled indications / [type 2 diabetes](https://healthrx.com/conditions-type-2-diabetes/diagnosis-algorithm) and CV risk reduction, not weight loss [1]

## Does Mounjaro need a dose adjustment in hepatic impairment?

No. The Mounjaro prescribing information states no dose adjustment for renal or hepatic impairment [1]. The usual schedule applies: start at 2.5 mg subcutaneously once weekly, then increase in 2.5 mg increments after at least 4 weeks on the current dose if more glycemic control is needed [1]. The maximum is 15 mg once weekly in adults and 10 mg once weekly in pediatric patients 10 years and older [1].

Mounjaro is indicated for type 2 diabetes in adults and children 10 years and older, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for those events [1]. It is not labeled for weight loss [1].

Questions worth asking

Choose the questions you want to keep Does a liver test result change how I should start Mounjaro? Which levels of liver impairment were included in the single-dose study? Does the label list any warning signs I should watch for if my liver is impaired? Should my prescriber check my liver tests during Mounjaro treatment? How far can a single-dose study predict how weekly dosing behaves in my liver? Which of my other medicines should I ask about before starting Mounjaro?

## What did the hepatic impairment study show?

A 2022 study in Clinical [Pharmacokinetics](https://healthrx.com/mounjaro/pharmacokinetics) evaluated tirzepatide in people with hepatic impairment and in people with normal hepatic function [2]. It was a parallel, single-dose, open-label study. Participants received one 5 mg subcutaneous dose. The groups were Child-Pugh A (n=6), Child-Pugh B (n=6), Child-Pugh C (n=7), and normal hepatic function (n=13) [2]. Participants could have type 2 diabetes or not [2].

[Tirzepatide](https://healthrx.com/zepbound/hepatic-impairment) exposure, based on the area under the drug concentration-time curve from zero to infinity and maximum observed concentration, was similar across the control and hepatic impairment groups [2]. The analysis found no difference in the geometric least-squares means for these parameters, and the 90% confidence intervals for the ratios spanned unity [2]. The study tested a single dose, not long-term weekly dosing [2].

A 2026 narrative review noted that safety data in people with advanced hepatic impairment remain limited and require further study [3].

## Which Mounjaro label warnings apply?

The label's warnings are general and are not specific to hepatic impairment. They include severe gastrointestinal adverse reactions, acute kidney injury due to volume depletion, acute pancreatitis, acute gallbladder disease, and hypoglycemia when Mounjaro is used with insulin or an insulin secretagogue [1]. The label says Mounjaro is not recommended in patients with severe gastroparesis [1]. It advises monitoring renal function in patients reporting adverse reactions that could lead to volume depletion, especially during initiation and escalation [1].

The label says to consider reducing the dose of a concomitant insulin secretagogue or insulin when starting Mounjaro to reduce hypoglycemia risk [1]. Contraindications are a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and known serious hypersensitivity to tirzepatide or an excipient [1].

## Does Mounjaro affect how other oral medicines are absorbed?

Tirzepatide delays gastric emptying and may affect the absorption of oral medicines [1]. The label advises caution when oral medicines are given with Mounjaro and says to monitor patients on oral medicines dependent on threshold concentrations for efficacy and those with a narrow therapeutic index, such as warfarin [1]. The label also advises people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose escalation [1]. Hormonal contraceptives that are not oral should not be affected [1].

## Is Mounjaro used for fatty liver disease?

Mounjaro's label lists type 2 diabetes and cardiovascular risk reduction as its indications; it does not list [fatty liver disease](https://healthrx.com/liver-masld/hepatic-steatosis) [1]. A 2020 phase 2 study in people with type 2 diabetes found that higher tirzepatide doses reduced some NASH-related blood biomarkers and increased [adiponectin](https://healthrx.com/labs-adiponectin/what-it-measures) over 26 weeks in post hoc analyses [4]. The study measured biomarkers, not liver outcomes [4].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, does the Mounjaro label require a dose adjustment for hepatic impairment?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Try the tool

Tirzepatide dose calculator and dosage chart

Convert a tirzepatide dose between mg, mL and U-100 syringe units, with the 2.5 to 15 mg label chart.

[Open the dose calculator](https://healthrx.com/tools/tirzepatide-dose-calculator)

Printable question sheet

Mounjaro hepatic impairment questions for your prescriber

Use this sheet before a visit about Mounjaro if you have a liver condition or liver test concerns. Fill in your history, gather your records, write down questions for your prescriber or pharmacist, and track what you notice between visits.

[Open the fill-in sheet](https://healthrx.com/printables/mounjaro/hepatic-impairment) Fill it in, print it or save it as a PDF. No sign-up.

Frequently asked questions

Does Mounjaro need a dose adjustment in liver disease?

No. The Mounjaro label states no dose adjustment for renal or hepatic impairment [1]. A single-dose study in people with Child-Pugh A, B or C impairment found similar tirzepatide exposure to people with normal liver function [2].

What starting dose is used in hepatic impairment?

The label gives one starting dose: 2.5 mg subcutaneously once weekly. It allows 2.5 mg increases after at least 4 weeks on the current dose if more glycemic control is needed [1].

Is Mounjaro studied in cirrhosis?

The single-dose pharmacokinetic study included people with Child-Pugh A, B and C impairment and found similar exposure to people with normal liver function [2]. A 2026 review noted that safety data in advanced hepatic impairment remain limited [3]. The label warns about severe gastrointestinal reactions and acute kidney injury from volume depletion in general [1].

Does Mounjaro interact with warfarin?

The label says tirzepatide delays gastric emptying and may affect absorption of oral medicines. It advises monitoring oral medicines dependent on threshold concentrations and those with a narrow therapeutic index, such as warfarin [1].

Is Mounjaro approved for fatty liver disease or weight loss?

Mounjaro's label lists type 2 diabetes in adults and children 10 years and older, and cardiovascular risk reduction in adults with type 2 diabetes at high risk; weight loss and fatty liver disease are not among the listed indications [1]. A 2020 phase 2 study reported changes in some NASH-related biomarkers in people with type 2 diabetes [4].

What is the maximum dose in hepatic impairment?

The label gives the same maximum as for other patients: 15 mg once weekly in adults, and 10 mg once weekly in pediatric patients 10 years and older [1].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Can you take Mounjaro with a liver condition?

The label says no dose adjustment is needed for hepatic impairment, and the usual schedule starts at 2.5 mg subcutaneously once weekly. A single-dose study found tirzepatide exposure in people with Child-Pugh A, B or C impairment was similar to people with normal liver function. A 2026 narrative review noted that safety data in people with advanced hepatic impairment remain limited.

Can you take tirzepatide with liver failure?

Safety in advanced hepatic impairment is not established. A 2026 narrative review noted that safety data in people with advanced hepatic impairment remain limited and require further study. The single-dose study included people with Child-Pugh C impairment, and after one 5 mg dose their tirzepatide exposure was similar to people with normal liver function.

References

Show all 4 references Hide references

1. U.S. National Library of Medicine, DailyMed. Mounjaro injection and KwikPen (tirzepatide) prescribing information. [Mounjaro injection and KwikPen (tirzepatide) label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)
2. Urva S, Quinlan T, Landry J, Ma X, Martin JA, Benson CT. [Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide](https://pubmed.ncbi.nlm.nih.gov/35674880/). Clin Pharmacokinet. 2022;61(7):1057-1067.
3. Kunutsor SK, Seidu S. [Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review](https://pubmed.ncbi.nlm.nih.gov/41351656/). Drugs. 2026;86(1):11-36.
4. Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, et al. [Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes](https://pubmed.ncbi.nlm.nih.gov/32291277/). Diabetes Care. 2020;43(6):1352-1355.

Next in this cluster

Related reading

- [tirzepatide Mounjaro dosing renal impairment](https://healthrx.com/mounjaro/renal-impairment)
- [tirzepatide Tirzepatide renal impairment](https://healthrx.com/zepbound/renal-impairment)
- [tirzepatide Mounjaro how to safely stop](https://healthrx.com/mounjaro/discontinuation-protocol)
- [tirzepatide Mounjaro in Special Populations](https://healthrx.com/mounjaro/special-populations)
- [tirzepatide Mounjaro History & Development](https://healthrx.com/mounjaro/history-development)
- [tirzepatide Mounjaro humana prior authorization](https://healthrx.com/mounjaro/humana-coverage)
- [tirzepatide Mounjaro Manufacturing, Supply & Shortage History](https://healthrx.com/mounjaro/manufacturing-supply)
- [tirzepatide Mounjaro mechanism of action](https://healthrx.com/mounjaro/mechanism-deep-dive)
- [tirzepatide Does Medicaid cover Mounjaro](https://healthrx.com/mounjaro/medicaid-coverage)
- [tirzepatide Mounjaro mental health](https://healthrx.com/mounjaro/mental-health-impact)
- [tirzepatide Mounjaro metabolism](https://healthrx.com/mounjaro/metabolism-thermogenesis)
- [tirzepatide Mounjaro Missed-Dose Protocol: What to Do and Why It Matters](https://healthrx.com/mounjaro/missed-dose-protocol)
- [type 2 diabetes What Is Mounjaro (Tirzepatide)? Complete Clinical Guide](https://healthrx.com/glp-1-faq/what-is-mounjaro-tirzepatide-calibrate)
- [tirzepatide Can you take Mounjaro with gabapentin](https://healthrx.com/interactions-mounjaro/with-gabapentin)

![mounjaro hepatic impairment: physician's desk with liver test report and unlabeled medicine bottle](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/mounjaro/hepatic-impairment.webp)

Clinicians review liver function results and medicine lists together to decide whether any dosing change is needed in hepatic impairment. Full mounjaro hepatic impairment guide and sources at [healthrx.com/mounjaro](https://healthrx.com/mounjaro).
